2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 852

Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Abstract Number: 853

Clinical Associations of Anti-Eukaryotic Initiation Factor 2B (anti-eIF2B) Antibodies in a Large Cohort of Patients with Anti-Nuclear Antibody Negative Systemic Sclerosis
Abstract Number: 854

The Ducas: Proposal for a Digital Ulcer Assessment Score in Scleroderma
Abstract Number: 855

The Relationship Between Systemic Sclerosis and Breast Cancer and the Effects on Treatment Outcome
Abstract Number: 856

Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy
Abstract Number: 857

Ultrasound Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis
Abstract Number: 858

Is There a Place for Repetitive 18f-Fluorodeoxyglucose Positron Emission Tomography in Giant-Cell Arteritis with Large-Vessel Involvement?
Abstract Number: 859

Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis
Abstract Number: 860

Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis
Abstract Number: 861

Efficacy of Methotrexate in Giant Cell Arteritis
Abstract Number: 862

Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis
Abstract Number: 863

Arterial Lesions in Giant Cell Arteritis
Abstract Number: 864

Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses
Abstract Number: 865

Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis
Abstract Number: 866

Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].